Transgene SA (TRGNF)
USD 1.59
(0.0%)
USD 1.59
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 31.23 Million EUR | 5.18% |
| 2022 | 33.25 Million EUR | -1.44% |
| 2021 | 33.73 Million EUR | 23.55% |
| 2020 | 27.3 Million EUR | -14.33% |
| 2019 | 31.87 Million EUR | 11.45% |
| 2018 | 28.6 Million EUR | -6.84% |
| 2017 | 30.7 Million EUR | 17.01% |
| 2016 | 26.23 Million EUR | -11.74% |
| 2015 | 29.72 Million EUR | -33.04% |
| 2014 | 44.39 Million EUR | -1.48% |
| 2013 | 45.05 Million EUR | -2.16% |
| 2012 | 46.05 Million EUR | 639.7% |
| 2011 | 6.22 Million EUR | 0.48% |
| 2010 | 6.19 Million EUR | 2.03% |
| 2009 | 6.07 Million EUR | 67.25% |
| 2008 | 3.63 Million EUR | -45.63% |
| 2007 | 6.67 Million EUR | 71.01% |
| 2006 | 3.9 Million EUR | 0.0% |
| 2004 | 24.18 Million EUR | -0.65% |
| 2003 | 24.34 Million EUR | 8.0% |
| 2002 | 22.53 Million EUR | -6.02% |
| 2001 | 23.98 Million EUR | -18.46% |
| 2000 | 29.41 Million EUR | 12.6% |
| 1999 | 26.11 Million EUR | -3.55% |
| 1998 | 27.07 Million EUR | 19.26% |
| 1997 | 22.7 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.21 Million EUR | 15.58% |
| 2024 Q2 | 2.21 Million EUR | 0.0% |
| 2023 Q4 | 1.91 Million EUR | -0.03% |
| 2023 FY | 34.97 Million EUR | 5.18% |
| 2023 Q1 | 2.65 Million EUR | -85.52% |
| 2023 Q2 | 18.01 Million EUR | 579.12% |
| 2023 Q3 | 1.91 Million EUR | -89.36% |
| 2022 Q4 | 18.32 Million EUR | 344.73% |
| 2022 FY | 33.25 Million EUR | -1.44% |
| 2022 Q2 | 20.08 Million EUR | 810.63% |
| 2022 Q3 | 4.12 Million EUR | -79.49% |
| 2022 Q1 | 2.2 Million EUR | -89.1% |
| 2021 Q1 | 577.5 Thousand EUR | -96.36% |
| 2021 Q3 | 1.53 Million EUR | -91.23% |
| 2021 FY | 33.73 Million EUR | 23.55% |
| 2021 Q2 | 17.5 Million EUR | 2931.69% |
| 2021 Q4 | 20.23 Million EUR | 1217.81% |
| 2020 Q3 | 2.41 Million EUR | -85.18% |
| 2020 Q1 | 3.61 Million EUR | -81.35% |
| 2020 Q2 | 16.26 Million EUR | 349.83% |
| 2020 Q4 | 15.86 Million EUR | 557.96% |
| 2020 FY | 27.3 Million EUR | -14.33% |
| 2019 Q2 | 17.3 Million EUR | 778.13% |
| 2019 Q1 | 1.97 Million EUR | -87.87% |
| 2019 Q3 | 2.26 Million EUR | -86.89% |
| 2019 Q4 | 19.38 Million EUR | 754.15% |
| 2019 FY | 31.87 Million EUR | 11.45% |
| 2018 FY | 28.6 Million EUR | -6.84% |
| 2018 Q1 | 1.65 Million EUR | -72.86% |
| 2018 Q2 | 1.65 Million EUR | 0.0% |
| 2018 Q3 | 16.25 Million EUR | 882.05% |
| 2018 Q4 | 16.25 Million EUR | 0.0% |
| 2017 FY | 30.7 Million EUR | 17.01% |
| 2017 Q4 | 6.09 Million EUR | 0.0% |
| 2017 Q2 | 8.73 Million EUR | 0.0% |
| 2017 Q1 | 8.73 Million EUR | 45.2% |
| 2017 Q3 | 6.09 Million EUR | -30.22% |
| 2016 Q2 | 6.31 Million EUR | 0.0% |
| 2016 FY | 26.23 Million EUR | -11.74% |
| 2016 Q4 | 6.01 Million EUR | 0.0% |
| 2016 Q3 | 6.01 Million EUR | -4.75% |
| 2016 Q1 | 6.31 Million EUR | -20.94% |
| 2015 FY | 29.72 Million EUR | -33.04% |
| 2015 Q4 | 7.99 Million EUR | 0.0% |
| 2015 Q2 | 11.27 Million EUR | 0.0% |
| 2015 Q3 | 7.99 Million EUR | -29.11% |
| 2015 Q1 | 11.27 Million EUR | 24.42% |
| 2014 Q4 | 9.06 Million EUR | 0.0% |
| 2014 Q3 | 9.06 Million EUR | -2.79% |
| 2014 Q1 | 9.32 Million EUR | -10.28% |
| 2014 FY | 44.39 Million EUR | -1.48% |
| 2014 Q2 | 9.32 Million EUR | 0.0% |
| 2013 Q2 | 10.68 Million EUR | 0.0% |
| 2013 Q4 | 10.38 Million EUR | 0.0% |
| 2013 Q3 | 10.38 Million EUR | -2.81% |
| 2013 FY | 45.05 Million EUR | -2.16% |
| 2013 Q1 | 10.68 Million EUR | 0.0% |
| 2012 FY | 46.05 Million EUR | 639.7% |
| 2011 FY | 6.22 Million EUR | 0.48% |
| 2010 FY | 6.19 Million EUR | 2.03% |
| 2009 FY | 6.07 Million EUR | 67.25% |
| 2008 FY | 3.63 Million EUR | -45.63% |
| 2007 FY | 6.67 Million EUR | 71.01% |
| 2006 FY | 3.9 Million EUR | 0.0% |
| 2005 Q1 | - EUR | 100.0% |
| 2005 Q2 | 6.01 Million EUR | 0.0% |
| 2004 Q3 | - EUR | -100.0% |
| 2004 Q2 | 5.68 Million EUR | -9.47% |
| 2004 Q1 | 6.28 Million EUR | -13.11% |
| 2004 Q4 | -24.18 Million EUR | 0.0% |
| 2004 FY | 24.18 Million EUR | -0.65% |
| 2003 Q2 | 5.83 Million EUR | -3.4% |
| 2003 FY | 24.34 Million EUR | 8.0% |
| 2003 Q3 | 5.24 Million EUR | -10.14% |
| 2003 Q1 | 6.03 Million EUR | -6.41% |
| 2003 Q4 | 7.22 Million EUR | 37.96% |
| 2002 Q2 | 5.32 Million EUR | -2.82% |
| 2002 FY | 22.53 Million EUR | -6.02% |
| 2002 Q1 | 5.48 Million EUR | -8.1% |
| 2002 Q3 | 5.26 Million EUR | -1.12% |
| 2002 Q4 | 6.45 Million EUR | 22.44% |
| 2001 Q2 | 6.16 Million EUR | -4.35% |
| 2001 FY | 23.98 Million EUR | -18.46% |
| 2001 Q4 | 5.96 Million EUR | 10.57% |
| 2001 Q3 | 5.39 Million EUR | -12.44% |
| 2001 Q1 | 6.44 Million EUR | -5.72% |
| 2000 Q1 | 7.8 Million EUR | 129.86% |
| 2000 FY | 29.41 Million EUR | 12.6% |
| 2000 Q4 | 6.83 Million EUR | -21.27% |
| 2000 Q3 | 8.67 Million EUR | 43.33% |
| 2000 Q2 | 6.05 Million EUR | -22.37% |
| 1999 Q1 | - EUR | 100.0% |
| 1999 FY | 26.11 Million EUR | -3.55% |
| 1999 Q2 | - EUR | 0.0% |
| 1999 Q4 | -26.11 Million EUR | 0.0% |
| 1999 Q3 | - EUR | 0.0% |
| 1998 Q4 | -28.61 Million EUR | 0.0% |
| 1998 Q1 | - EUR | 0.0% |
| 1998 Q2 | - EUR | 0.0% |
| 1998 Q3 | - EUR | 0.0% |
| 1998 FY | 27.07 Million EUR | 19.26% |
| 1997 FY | 22.7 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 64.013% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -535.046% |
| SQZ Biotechnologies Company | 85.61 Million USD | 63.523% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -5.678% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 16.171% |
| Mesoblast Limited | 5.9 Million USD | -429.16% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -1979.434% |
| Genus plc | 147.7 Million USD | 78.855% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -255.737% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2227.988% |
| Marizyme, Inc. | 19.23 Million USD | -62.325% |
| ContraFect Corporation | 56.88 Million USD | 45.102% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -274.517% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -608.399% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -2011.984% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -970.936% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -1019.247% |
| MultiCell Technologies, Inc. | 567.42 USD | -5503935.811% |
| Accustem Sciences Inc. | 3.74 Million USD | -733.623% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 63.662% |
| EV Biologics, Inc. | 531.96 Thousand USD | -5770.908% |
| Q BioMed Inc. | 3.43 Million USD | -808.769% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -26.365% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -7916.87% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -1088.61% |
| Biomind Labs Inc. | 994.18 Thousand USD | -3041.377% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 86.15% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -364.884% |
| Skye Bioscience, Inc. | 13.54 Million USD | -130.529% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -1424.426% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 125024.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -519.411% |
| IMV Inc. | 37.7 Million USD | 17.179% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -95.069% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -1601.874% |
| GB Sciences, Inc. | 1.42 Million USD | -2098.578% |
| Alpha Cognition Inc. | 9.7 Million USD | -221.783% |
| HST Global, Inc. | 140.9 Thousand USD | -22064.264% |
| CSL Limited | 3.44 Billion USD | 99.094% |
| Halberd Corporation | 74.84 Thousand USD | -41629.243% |
| Enzolytics Inc. | 2.17 Million USD | -1332.939% |
| Resverlogix Corp. | 12.71 Million USD | -145.681% |
| Affymax, Inc. | 39.38 Million USD | 20.705% |
| SYBLEU INC | 160.87 Thousand USD | -19313.088% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -755.478% |
| argenx SE | 1.53 Billion USD | 97.963% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 45.628% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -2891.475% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -1877.453% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -817.216% |
| AVAX Technologies, Inc. | 7.31 Million USD | -327.221% |
| Zenith Capital Corp. | 8.94 Million USD | -249.223% |
| Genscript Biotech Corporation | 825.34 Million USD | 96.216% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -179172.143% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -1171.974% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -18109.54% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 68.558% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -1674.813% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -1483.695% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -1575.15% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -187.393% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -1525.847% |
| BioStem Technologies, Inc. | 22.97 Million USD | -35.936% |
| ONE Bio Corp. | 6.44 Million USD | -384.661% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -17108.585% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -2238.646% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -2676.311% |
| Agentix Corp. | 1.37 Million USD | -2176.717% |
| LadRx Corporation | 3.81 Million USD | -719.326% |
| Cell Source, Inc. | 4.32 Million USD | -622.046% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -7416.866% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3281.772% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -3281.772% |
| NovAccess Global Inc. | 2.46 Million USD | -1166.073% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -1198.622% |
| Itoco Inc. | 919.14 Thousand USD | -3297.839% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -636.856% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -2690.974% |
| Kadimastem Ltd | 2.41 Million USD | -1195.832% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -11832.708% |
| CytoDyn Inc. | 18.05 Million USD | -72.948% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -123985.184% |
| Mobile Lads Corp. | 554.54 Thousand USD | -5531.814% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -14090.878% |
| Qrons Inc. | 643.67 Thousand USD | -4751.968% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -2099.688% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -1300.569% |
| Rebus Holdings, Inc. | 664 Thousand USD | -4603.464% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -1619.466% |
| International Stem Cell Corporation | 5.27 Million USD | -492.506% |
| Bioxytran, Inc. | 3.82 Million USD | -717.534% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -59227.153% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -153422.096% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 13.884% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -1830.222% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -4144.294% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -903.889% |
| Neutra Corp. | 243.82 Thousand USD | -12708.987% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -78.902% |
| PureTech Health plc | 144.59 Million USD | 78.401% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -52.422% |
| IXICO plc | 4.7 Million USD | -563.501% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -255.019% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 73.476% |
| CSL Limited | 3.89 Billion USD | 99.198% |
| Cellectis S.A. | 97.32 Million USD | 67.909% |